Aroa Biosurgery has published one of the largest prospective real-world evaluations yet of an extracellular-matrix bioscaffold used in complex soft tissue reconstruction, reporting interim safety results from 411 patients with 474 defects treated at 10 U.S. centers. The MASTRR Registry analysis found that 12.2% of patients experienced at least one adverse event, but investigators classified no event as definitely related to the ovine forestomach matrix devices and considered just one event, representing 0.2% of subjects, probably device related. At the treated defect itself, superficial infection occurred in 2.9% of defects, dehiscence in 3.2% and deep tissue infection in 0.7%.
Those rates deserve attention because this was not a registry dominated by straightforward clean surgical incisions. Almost 60% of the defects were chronic, 38.2% were classified as CDC class II and 50.4% as class III, meaning nearly nine in ten were clean-contaminated or contaminated. Osteomyelitis was present in 15% of defects, exposed structures in 11.4%, and the cohort included diabetic foot ulcers, traumatic injuries, ostomy takedowns and pilonidal disease alongside other difficult reconstructive problems.
What is Myriad and why would surgeons place a sheep-derived matrix into a wound?
Myriad Matrix is an extracellular matrix bioscaffold derived from ovine forestomach tissue. Rather than functioning as a permanent synthetic implant, the material provides a temporary biological structure into which the patient’s cells and blood vessels can migrate while tissue remodeling occurs.
Aroa’s product information describes the matrix as retaining naturally occurring extracellular-matrix components including collagen-associated structures, elastin, fibronectin, glycosaminoglycans and laminin. The device gradually becomes incorporated into surrounding tissue as healing progresses.
The underlying idea is that tissue reconstruction requires more than covering a hole. Cells need a three-dimensional environment through which they can migrate, vascularize the region and deposit new matrix. Bioscaffolds are intended to provide that temporary architecture.
Myriad Matrix can be used in plastic and reconstructive surgery and in the management of several wound types, including partial- and full-thickness wounds, diabetic ulcers, surgical wounds, trauma wounds and wounds with undermining or tunneling.
Aroa also sells Myriad Morcells, a particulate format designed to conform to irregular wound beds. The FDA granted 510(k) clearance for the particulate product in 2021, while Myriad Matrix traces its U.S. regulatory history to an earlier 510(k) pathway.
Why is the MASTRR population more informative than a collection of easy wounds?
A safety profile can look artificially favorable if a device is used mainly in healthy patients with clean wounds and good blood supply. MASTRR deliberately captures routine practice across specialties and therefore includes patients with diabetes, vascular problems, severe systemic disease, contamination and chronic tissue defects.
In the interim analysis, 53% of subjects were classified as ASA class III, a category generally reflecting severe systemic disease, while another 32.4% were ASA class II. Median age was 54, 69.3% were male and the cohort included a substantial burden of medical complexity.
The defects themselves were diverse. Diabetic foot ulcers represented 22.6%, traumatic wounds 16.5%, ostomy takedowns 11.2% and pilonidal sinuses 10.8%, with additional reconstructive indications across trauma, colorectal, burns and limb salvage.
This heterogeneity makes the safety observations more relevant to actual reconstructive surgery. It also makes effectiveness harder to measure because wounds with profoundly different biology, anatomy and treatment goals cannot be pooled casually into one healing endpoint.
That is why the interim publication focuses principally on safety.
How low were infection and wound-complication rates?
Superficial infection involving the index defect occurred in 2.9% of cases, deep tissue infection in 0.7% and wound dehiscence in 3.2%. Across the full 411-patient cohort, 59 adverse events were reported in 50 people, corresponding to 12.2% experiencing one or more events.
Only one event was considered probably related to the device, and none was considered definitely related. Eight patients died during registry follow-up, but investigators attributed those deaths to substantial pre-existing disease or unrelated medical complications rather than the index reconstruction or bioscaffold.
Median follow-up was 27.1 weeks, giving the registry more opportunity to capture complications than a study limited to immediate postoperative events.
These numbers look favorable in a medically complicated cohort, but they must not be converted into a claim that Myriad “reduces infections.” There is no randomized control group in this interim analysis, so the study cannot determine what the infection rate would have been if comparable wounds were reconstructed with another matrix, flap, graft or standard surgical approach.
Why does contamination matter when evaluating a biological scaffold?
Implanting or placing biomaterial into an infected or heavily contaminated field can create concern about persistent infection. Synthetic materials in particular may provide surfaces on which bacterial biofilms can establish themselves, although risk varies greatly according to device type and procedure.
Biological scaffolds are often considered for difficult reconstructive environments partly because they are remodeled rather than remaining indefinitely as an inert permanent structure. But “biological” does not mean infection-proof.
Myriad’s own instructions caution against application in uncontrolled clinical infection, acute inflammation, excessive exudate or bleeding. They also identify infection, inflammation, allergic reaction and seroma among potential complications.
The MASTRR finding is therefore best understood as evidence that the products have been used with relatively low reported device-related complication rates even in contaminated and chronically difficult defects, not as permission to disregard wound-bed preparation or infection control.
Patient selection, surgical debridement, antimicrobial treatment and postoperative management remain critical.
What is unusual about ovine forestomach matrix compared with conventional wound coverings?
A simple dressing protects a wound surface and manages moisture or exudate. An extracellular-matrix scaffold is intended to participate more actively in tissue reconstruction by providing biological architecture that cells can infiltrate.
Aroa processes tissue from sheep forestomach to create a non-reconstituted matrix retaining elements of its original extracellular architecture. Myriad Matrix is offered in multilayer formats and engineered to provide spaces and perforations through which cells can move.
Over time, the scaffold is expected to be replaced as host tissue remodels the region. The commercial category sits between traditional wound care and more complex reconstructive surgery.
This makes clinical evaluation difficult. Success can involve different endpoints depending on whether the surgeon is treating an exposed tendon, reconstructing a diabetic foot defect, managing a fistula or preparing a wound for later skin grafting.
A registry is useful because it shows how a product behaves across that heterogeneity. A randomized trial is more useful when the goal is to prove superiority for one clearly defined indication.
Does the registry establish that Myriad heals wounds better than competing bioscaffolds?
No. MASTRR is observational and single-arm. It has no randomized comparator and therefore cannot establish that Myriad produces faster closure, fewer operations, shorter hospital stays or lower infection rates than another product.
Selection bias is possible because surgeons decide when to use the device. Differences in debridement, antibiotics, negative-pressure wound therapy, vascular status and reconstructive technique could all influence outcomes.
The investigators describe the registry as a prospective real-world surveillance mechanism, which is precisely where its value lies. It provides broader safety evidence than a small tightly selected case series and can identify uncommon or unexpected problems as exposure expands.
The study is ultimately approved to enroll as many as 800 patients, so the interim 411-patient dataset represents roughly half of the intended registry population.
A later effectiveness analysis may provide more insight into tissue formation, closure and additional procedures, but comparative questions will still require careful control for patient differences.
Why are real-world registries becoming more important for medical devices?
Medical devices often evolve differently from drugs. Surgeons develop experience, procedures are refined and products may be used across multiple anatomies that would be difficult to capture in one randomized trial.
A registry allows investigators to observe performance as the device moves into ordinary clinical practice. That can expose problems that are absent in highly selected pivotal studies and show whether results remain stable across different hospitals and surgical specialties.
The trade-off is weaker causal inference. Because treatment is not randomized, registries are much better at answering “what happened when this device was used?” than “did this device cause a better outcome than the alternative?”
MASTRR demonstrates that distinction well. Its large, heterogeneous wound population gives confidence that Myriad has been deployed across genuinely difficult cases without an obvious broad safety signal. It does not tell us how many of those patients would have done equally well without Myriad.
What do the FDA clearances mean for the Myriad portfolio?
Myriad products are already commercial medical devices rather than experimental scaffolds entering a first-in-human study. Aroa received U.S. 510(k) clearance for its matrix technology years ago, and Myriad Morcells subsequently received clearance as a morcellized wound-management format.
A 510(k) decision means the FDA determined that the submitted device was substantially equivalent to an appropriate legally marketed predicate for the specified intended use. It should not be described as proof that the device has been shown superior to other wound products.
The registry therefore performs a different job from premarket clearance. It generates post-commercial clinical evidence about how the devices behave in complex real-world reconstruction.
That evidence can influence surgeons and payers even when it does not change the regulatory label.
What should reconstructive surgeons watch as MASTRR moves toward 800 patients?
The final registry population should provide more precise estimates of uncommon adverse events and potentially allow meaningful subgroup analyses. Outcomes in diabetic foot wounds may differ from trauma or colorectal defects, and surgeons need indication-specific information rather than one pooled safety percentage.
Another important question is repeat application. The current paper says only a single application was required in most patients, which could have implications for procedure burden and cost if reproduced across well-defined indications.
Longer follow-up could also clarify reoperation rates, grafting requirements and durability of reconstructed tissue.
For now, the most defensible conclusion is that Aroa has accumulated unusually broad prospective evidence for a soft-tissue bioscaffold. In 411 medically complicated patients with 474 defects, including a large contaminated-wound population, no adverse event was judged definitely related to the device and only one was considered probably related. That is a meaningful safety signal. Demonstrating comparative effectiveness is the next, harder question.
